Scientific Fellow Evaluation

Description

Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to research in oncology and infectious diseases in order to improve patient outcomes and quality of life. Our main activities include drug development, drug manufacturing and digital health investment. Debiopharm International SA aims to develop innovative therapies that target high unmet medical needs. Our unique “development only” business model allows us to act as a bridge between disruptive discovery products and patient access in international markets. We first identify high-potential compounds for in-licensing, clinically demonstrate their safety and efficacy and then select large pharmaceutical commercialization partners to maximize patient access globally.

At Debiopharm you will be at the forefront of the fight against cancer and infectious diseases, and you will have the opportunity to work on new innovative medicines for patients. Efficiency is our mode of action, saving lives our collective target.

For our Search & Evaluation team based at our Headquarters in Lausanne, we are looking for a

Scientific Fellow Evaluation - Oncology (6 months internship)

Are you interested in developing your knowledge of the Life Sciences industry ? Are you looking for a unique chance to join an innovative company with a unique business model ?

Join our Evaluation team and be at the forefront of our development strategy by conducting the scientific evaluation of new opportunities for a potential entry in our oncology pipeline. In this role, you will evaluate new pipeline opportunities by conducting a scientific analysis and presenting recommendations to the S&E team, in view of pursuing the evaluation of the presented programs.

Coached by a team of dynamic experts, you will have a unique opportunity to be exposed to worldwide innovative science and critical strategic decisions at the initiation of the research and development of key assets for the company.

**Your responsibilities will be but not limited to**:
Evaluate new opportunities in Oncology based on scientific and strategic criteria provided by the Director Search & Evaluation Oncology;
Present the evaluated new opportunities at weekly triage meetings and propose positive, negative or alternative recommendations on the discussed programs;
Elaborate the scientific questions to be discussed with the potential external partner and participate in the programs discussions with our partners;
Review the literature and the competitive landscape of targets of interest discussed at triage.
Complete the information provided by the potential partners by searching additional insights in internal and external databases.
**Requirements**:
Advanced University degree in Cancer Research (PhD or equivalent)
First working experience in pharma/biotech is an asset;
Proficient in desk-research activities with excellent ability to synthetize
Demonstrates exceptional resilience and ability to remain calm under pressure.
Excellent command of English (written and verbal), French is a plus
Outgoing personality and good communication skills
Excellent organizational and planning skills, with the ability to manage multiple priorities and meet deadlines
Proactive mindset, with good ability to anticipate issues and propose solutions
Willingness to learn and curiosity
Adaptability and flexibility in a fast-paced and changing environment

**Benefits**:
Debiopharm can offer you

The opportunity to join a successful company, at the forefront of the most advanced scientific developments in the industry and be exposed to many areas within clinical development and the pharmaceutical industry
The possibility to be in a company in which innovation, people and entrepreneurship are the fundamentals of its success
Proud to be an Equal-Pay certified, we ensure offering to all our employees the same opportunities

Submission of unsolicited resumes in advance of an agreement between the Human Resources Department and the external staffing agency or recruiter does not create any implied obligation on the part of Debiopharm.